CUR - Neuralstem, Inc.
| Previous Close | 1.66 |
| Open | 1.66 |
| Bid | 0.00 x 0 |
| Ask | 0.00 x 0 |
| Day's Range | 1.59 - 1.66 |
| 52 Week Range | 0.88 - 6.60 |
| Volume | 58,800 |
| Avg. Volume | 190,416 |
| Market Cap | 24.711M |
| Beta | 0.42 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- SmarterAnalyst•5 months ago
Neuralstem, Inc. (CUR): Updated Phase II Trial Success in Major Depressive Disorder Takes the Street by Storm
Neuralstem (NASDAQ:CUR) stock is on fire after revealing a huge clinical win that has sent bulls storming the market today to buy into piece of the biotech action. Shares are rocketing 100% on back of the drug maker's successful updated Phase 2 clinical data in major depressive disorder, where the company's NSI-189 asset impressed at the 56th American College of Neuropsychopharmacology (ACNP) Annual meeting.
- Simply Wall St.•5 months ago
Does Neuralstem Inc’s (CUR) Past Performance Indicate A Stronger Future?
Examining Neuralstem Inc’s (NASDAQ:CUR) past track record of performance is an insightful exercise for investors. It allows us to reflect on whether or not the company has met or exceedRead More...
- Associated Press•5 months ago
Neuralstem reports 3Q loss
On a per-share basis, the Germantown, Maryland-based company said it had a loss of 18 cents. The biopharmaceutical company posted revenue of $2,500 in the period. Its adjusted revenue was $3,000. The company's ...
- Capital Cube•6 months ago
ETFs with exposure to Neuralstem, Inc. : November 10, 2017
Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Neuralstem, Inc. Here are 5 ETFs with the largest exposure to CUR-US. Comparing the performance and risk of Neuralstem, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker Fund Name ... Read more (Read more...)
Capital Cube•6 months agoNeuralstem, Inc. :CUR-US: Earnings Analysis: Q3, 2017 By the Numbers : November 9, 2017
Categories: Yahoo FinanceGet free summary analysis Neuralstem, Inc. reports financial results for the quarter ended September 30, 2017. We analyze the earnings along side the following peers of Neuralstem, Inc. – Cytokinetics, Incorporated, Geron Corporation, Acorda Therapeutics, Inc., Aceto Corporation, Intra-Cellular Therapies, Inc., Supernus Pharmaceuticals, Inc. and Neurocrine Biosciences, Inc. (CYTK-US, GERN-US, ACOR-US, ACET-US, ITCI-US, SUPN-US and ... Read more (Read more...)
- Simply Wall St.•6 months ago
One Thing To Consider Before Buying Neuralstem Inc (CUR)
For Neuralstem Inc’s (NASDAQ:CUR) shareholders, and also potential investors in the stock, understanding how the stock’s risk and return characteristics can impact your portfolio is important. Every stock in theRead More...
- TheStreet.com•8 months ago
Intra-Cellular Leaps; Schizophrenia Drug Shows Less Side Effects-Biotech Movers
Standard treatments can cause motor side effects and/or weight gain, cardiovascular complications, dyslipidemia, and hyperglycemia.
- Capital Cube•8 months ago
ETFs with exposure to Neuralstem, Inc. : August 31, 2017
Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Neuralstem, Inc. Here are 5 ETFs with the largest exposure to CUR-US. Comparing the performance and risk of Neuralstem, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker Fund Name ... Read more (Read more...)
Capital Cube•8 months agoNeuralstem, Inc. :CUR-US: Earnings Analysis: Q2, 2017 By the Numbers : August 24, 2017
Categories: Yahoo FinanceGet free summary analysis Neuralstem, Inc. reports financial results for the quarter ended June 30, 2017. We analyze the earnings along side the following peers of Neuralstem, Inc. – Titan Pharmaceuticals, Inc., Cytokinetics, Incorporated, Acorda Therapeutics, Inc., Geron Corporation, Neurocrine Biosciences, Inc., Albany Molecular Research, Inc., BioTime, Inc., Charles River Laboratories International, Inc. and Repligen ... Read more (Read more...)
- Associated Press•9 months ago
Neuralstem reports 2Q loss
The Germantown, Maryland-based company said it had a loss of 39 cents per share. The biopharmaceutical company posted revenue of $2,500 in the period. Its adjusted revenue was $3,000. The company's shares ...
- Capital Cube•10 months ago
ETFs with exposure to Neuralstem, Inc. : July 4, 2017
Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Neuralstem, Inc. Here are 5 ETFs with the largest exposure to CUR-US. Comparing the performance and risk of Neuralstem, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker Fund Name ... Read more (Read more...)
- Capital Cube•11 months ago
ETFs with exposure to Neuralstem, Inc. : June 2, 2017
Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Neuralstem, Inc. Here are 5 ETFs with the largest exposure to CUR-US. Comparing the performance and risk of Neuralstem, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker Fund Name ... Read more (Read more...)
- Capital Cube•11 months ago
ETFs with exposure to Neuralstem, Inc. : May 11, 2017
Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Neuralstem, Inc. Here are 5 ETFs with the largest exposure to CUR-US. Comparing the performance and risk of Neuralstem, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker Fund Name ... Read more (Read more...)
- Associated Press•last year
Neuralstem reports 1Q loss
The Germantown, Maryland-based company said it had a loss of 68 cents per share. Losses, adjusted for non-recurring costs, were 43 cents per share. The biopharmaceutical company posted revenue of $2,500 ...
